TB-500 Fragment (17-23) 10mg

$100.00

TB-500 Fragment (17-23) is a research peptide consisting of a short amino acid sequence derived from the actin-binding region of Thymosin Beta-4. It has been shown in preclinical studies to regulate cell migration, angiogenesis, and cytoskeletal organization through modulation of actin polymerization. This fragment is used in experimental research investigating wound repair, tissue remodeling, and peptide-mediated regenerative signaling mechanisms.

For research use only. Not for human consumption.

References:
Goldstein AL et al., Ann NY Acad Sci, 2007 1112:148–154
Huff T et al., J Mol Biol, 2001 312(3):593–606
Malinda KM et al., FASEB J, 1999 13(14):2106–2114

TB-500 Fragment (17-23), also called fequesetide or (17) (LKKTETQ) (23), represents the smallest portion of the thymosin beta-4 molecule that retains the larger protein’s active binding domain. Research indicates that this synthetic derivative of thymosin beta-4 is capable of binding to actin, the molecule inside of cells that is responsible for improved cell structure, movement (a.k.a. migration), and replication. By altering the function of actin in cells, TB-500 Fragment (17-23) has been shown to modulate the immune response and alter cell migration patterns. This can lead to large-scale changes in tissue/organ structure and function. In animal models, these changes have been shown to accelerate wound healing, decrease inflammation, promote blood vessel growth, reduce scar formation, improve musculoskeletal function, and help to slow or reverse the course of certain disease conditions.

SKU: 134 Category: All Peptides

Description

TB-500 Fragment (17-23) 10mg – Buy High-Quality TB-500 Fragment (17-23) 10mg Online

Looking to buy TB-500 Fragment (17-23) 10mg for your research laboratory? You have come to the right place.
We currently have TB-500 Fragment (17-23) 10mg for sale and it is in stock and ready for immediate shipping.
Our TB-500 Fragment (17-23) 10mg is of the highest purity, making it the best TB-500 Fragment (17-23) 10mg online for scientific studies.

Product Overview

TB-500 Fragment (17-23) 10mg is a premium research compound widely utilized in various scientific studies.
Researchers seeking to buy TB-500 Fragment (17-23) 10mg online often prioritize purity and consistency.
This compound has been studied extensively for its unique biochemical properties and its role in cellular pathways.

Overview

Thymosin Beta-4 Fragment (17–23), also known as fequesetide (LKKTETQ), is a synthetic heptapeptide corresponding to a conserved actin-interaction domain derived from the larger thymosin beta-4 polypeptide. This fragment is utilized in laboratory research settings as a molecular probe for investigating cytoskeletal organization, actin dynamics, and intracellular signaling processes.

All observations associated with this peptide originate from in-vitro systems and controlled in-vivo animal models. No clinical, diagnostic, or therapeutic interpretations are implied.

Biochemical Characteristics

TB-500 Fragment (17-23) molecular structure

Amino Acid Sequence: LEU-LYS-LYS-THR-GLU-THR-GLN (LKKTETQ)
Chemical Formula: C36H66N10O13
Molecular Weight: 846.97 g/mol
PubChem CID: 10169788
CAS Number: 476014-70-7
Synonyms: Fequesetide; Thymosin Beta-4 (17–23)

The peptide lacks disulfide bonds and exhibits physicochemical properties suitable for aqueous laboratory systems. Structural simplicity enables reproducible synthesis and analytical verification.

Research Applications

Thymosin Beta-4 Fragment (17–23) is employed exclusively in research environments to examine:

Actin monomer sequestration and filament assembly
Cellular migration and cytoskeletal remodeling
Intracellular signal transduction pathways
Protein–protein interaction dynamics
Regulation of inflammatory mediators in animal models

All applications are limited to non-clinical experimental models.

Pathway / Mechanistic Context

Mechanistic investigations indicate that the fragment participates in modulation of actin polymerization processes. Interaction with actin-regulatory complexes such as Arp2/3 has been explored in preclinical models, highlighting its utility for studying branched actin network formation.

Actin branching schematic

Downstream signaling pathways associated with cytoskeletal organization, including focal adhesion kinase–related cascades and PI3K/Akt-associated signaling, have been examined in vitro using this peptide as a research tool.

Preclinical Research Summary

Published preclinical literature describes investigation of thymosin beta-4–derived fragments in rodent and cellular systems. Experimental observations include modulation of fibroblast migration, endothelial cell organization, and cytokine signaling under controlled laboratory conditions.

Additional studies in neural and musculoskeletal animal models have explored molecular responses related to cytoskeletal plasticity, inflammatory mediator balance, and cellular differentiation markers. These findings are presented strictly as experimental observations without clinical extrapolation.

Form & Analytical Testing

This product is supplied as a lyophilized synthetic peptide produced via solid-phase peptide synthesis. Each batch is characterized using high-performance liquid chromatography and mass spectrometry to confirm identity and purity.

Analytical documentation supports reproducibility for laboratory workflows.

About The Author

The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Scientific Journal Author

Geoffrey M. Cooper is professor of biology at Boston University. He served as chair of the department of biology for a number of years, and subsequently as associate dean of the faculty for the natural sciences in the university’s college of arts & sciences.

Cooper earned his Ph.D. at the University of Miami in 1973, and was a postdoctoral fellow with nobel laureate, Howard Temin. His work includes cellular growth control, cancer, and signal transduction. More specifically, he focuses on “the roles of proto-oncogene proteins as elements of signal transduction pathways that control proliferation, differentiation, and survival of mammalian cells.”

Geoffrey M. Cooper is being referenced as one of the leading scientists involved in the research and development of TB-500 Fragment (17-23). In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Geoffrey M. Cooper is listed in [2] under the referenced citations.

Resources

V. Papalazarou and L. M. Machesky, “The cell pushes back: The Arp2/3 complex is a key orchestrator of cellular responses to environmental forces,” Curr. Opin. Cell Biol., vol. 68, pp. 37–44, Feb. 2021, doi: 10.1016/j.ceb.2020.08.012.
G. M. Cooper, “The Cytoskeleton and Cell Movement,” in The Cell: A Molecular Approach. 2nd edition, Sinauer Associates, 2000. Accessed: Apr. 10, 2024. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK9893/
“18.1: Introduction,” Biology LibreTexts. Accessed: Apr. 10, 2024. [Online]. Available: https://bio.libretexts.org/Under_Construction/Cell_and_Molecular_Biology_(Bergtrom)/18:_The_Cytoskeleton_and_Cell_Motility/18.01:_Introduction
PubChem, “Lkktetq.” Accessed: Apr. 10, 2024. [Online]. Available: https://pubchem.ncbi.nlm.nih.gov/compound/10169788
S. Lv, H. Cai, Y. Xu, J. Dai, X. Rong, and L. Zheng, “Thymosin-β 4 induces angiogenesis in critical limb ischemia mice via regulating Notch/NF-κB pathway,” Int. J. Mol. Med., vol. 46, no. 4, pp. 1347–1358, Oct. 2020, doi: 10.3892/ijmm.2020.4701.
G. Sosne, P. Qiu, and M. Kurpakus-Wheater, “Thymosin beta-4 and the eye: I can see clearly now the pain is gone,” Ann. N. Y. Acad. Sci., vol. 1112, pp. 114–122, Sep. 2007, doi: 10.1196/annals.1415.004.
S. S. Iyer and G. Cheng, “Role of Interleukin 10 Transcriptional Regulation in Inflammation and Autoimmune Disease,” Crit. Rev. Immunol., vol. 32, no. 1, pp. 23–63, 2012.
A. Carracedo and P. P. Pandolfi, “The PTEN-PI3K pathway: of feedbacks and cross-talks,” Oncogene, vol. 27, no. 41, pp. 5527–5541, Sep. 2008, doi: 10.1038/onc.2008.247.
G. Song, G. Ouyang, and S. Bao, “The activation of Akt/PKB signaling pathway and cell survival,” J. Cell. Mol. Med., vol. 9, no. 1, pp. 59–71, Jan. 2005, doi: 10.1111/j.1582-4934.2005.tb00337.x.
J. P. Alao, “The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention,” Mol. Cancer, vol. 6, p. 24, Apr. 2007, doi: 10.1186/1476-4598-6-24.
Y. Xiong et al., “Neuroprotective and neurorestorative effects of thymosin β4 treatment following experimental traumatic brain injury,” Ann. N. Y. Acad. Sci., vol. 1270, pp. 51–58, Oct. 2012, doi: 10.1111/j.1749-6632.2012.06683.x.
D. C. Morris et al., “A dose-response study of thymosin β4 for the treatment of acute stroke,” J. Neurol. Sci., vol. 345, no. 1–2, pp. 61–67, Oct. 2014, doi: 10.1016/j.jns.2014.07.006.
J. Zhang et al., “Thymosin beta4 promotes oligodendrogenesis in the demyelinating central nervous system,” Neurobiol. Dis., vol. 88, pp. 85–95, Apr. 2016, doi: 10.1016/j.nbd.2016.01.010.
M. Santra et al., “Thymosin β4 up-regulation of microRNA-146a promotes oligodendrocyte differentiation and suppression of the Toll-like proinflammatory pathway,” J. Biol. Chem., vol. 289, no. 28, pp. 19508–19518, Jul. 2014, doi: 10.1074/jbc.M113.529966.
M. Severa et al., “Thymosins in multiple sclerosis and its experimental models: moving from basic to clinical application,” Mult. Scler. Relat. Disord., vol. 27, pp. 52–60, Jan. 2019, doi: 10.1016/j.msard.2018.09.035.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

RUO Disclaimer

The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.

For Laboratory Research Only. Not for human use, medical use, diagnostic use, or veterinary use.

COA COA COA

TEST RESULTS

Storage Instructions:

All of our products are manufactured using the Lyophilization (Freeze Drying) process, which ensures that our products remain 100% stable for shipping for up to 3-4 months.
Once the peptides are reconstituted (mixed with bacteriostatic water), they must be stored in the fridge to maintain stability. After reconstitution, the peptides will remain stable for up to 30 days.

Lyophilization is a unique dehydration process, also known as cryodesiccation, where the peptides are frozen and then subjected to low pressure. This causes the water in the peptide vial to sublimate directly from solid to gas, leaving behind a stable, crystalline white structure known as lyophilized peptide. The puffy white powder can be stored at room temperature until you’re ready to reconstitute it with bacteriostatic water.

Once peptides have been received, it is imperative that they are kept cold and away from light. If the peptides will be used immediately, or in the next several days, weeks or months, short-term refrigeration under 4C (39F) is generally acceptable. Lyophilized peptides are usually stable at room temperatures for several weeks or more, so if they will be utilized within weeks or months such storage is typically adequate.

However, for longer term storage (several months to years) it is more preferable to store peptides in a freezer at -80C (-112F). When storing peptides for months or even years, freezing is optimal in order to preserve the peptide’s stability.

Why Choose Our TB-500 Fragment (17-23) 10mg?

When you are looking for TB-500 Fragment (17-23) 10mg for sale, quality is paramount.
Our products undergo rigorous testing to ensure they meet the strict requirements of laboratory environments.
By choosing to buy TB-500 Fragment (17-23) 10mg from our store, you are guaranteed a product that is:

High Purity (Tested for 99%+)
Fast Shipping – Always in stock
Secure Packaging for Research Integrity
Competitive Pricing for Bulk Orders

Specifications & Technical Data

Feature	Specification
Product Name	TB-500 Fragment (17-23) 10mg
SKU	134
Purity	>99%
Form	Research Grade Compound
Availability	In Stock / For Sale

Scientific Research & Clinical Applications

The research surrounding TB-500 Fragment (17-23) 10mg is vast. Scientists explore its potential in various metabolic and physiological models.
For more detailed scientific data, you can visit PubMed
to review the latest peer-reviewed literature regarding this compound.

Frequently Asked Questions

Where can I buy TB-500 Fragment (17-23) 10mg?

You can buy TB-500 Fragment (17-23) 10mg directly from our website. We provide a secure checkout and fast shipping to ensure your research stays on track.

Is TB-500 Fragment (17-23) 10mg in stock?

Yes, we currently have TB-500 Fragment (17-23) 10mg in stock. Orders are typically processed within 24 hours to ensure rapid delivery to your laboratory.